Compare Alphabet Inc Class A (GOOGL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Alphabet (GOOGL) trades at $353.78, up 0.3% with strong technical momentum as price approaches resistance at $356. The stock shows robust fundamentals with Q2 2026 EPS beating expectations at $9.11 versus $2.87, continuing a pattern of earnings outperformance. Revenue growth accelerated to $402.84 billion in 2025 with net income margins expanding to 32.8%. Analyst sentiment remains overwhelmingly positive with 87% buy ratings and a $430.96 consensus target, though RSI levels suggest potential near-term overbought conditions.

Alphabet presents a compelling growth story with AI-driven expansion and strong financial execution. The primary investment opportunity lies in continued AI leadership and cloud growth, while risks include antitrust scrutiny and tech sector volatility. With valuation metrics remaining reasonable (P/E 17.75) despite strong performance, the stock offers balanced upside potential for long-term investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.